Pharmabiz1d
Bioretec inks sales and distribution pact to speed-up the commercialization of RemeOs Trauma Screw in US market
Bioretec Ltd, a pioneering company dedicated to advancing biodegradable orthopaedic implants, is moving ahead with the next phase of the commercialization of its innovative RemeOs Trauma Products in ...
Pharmabiz1d
Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children
Zenyaku Kogyo receives Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat chronic ITP in children: Tokyo Saturday, November 23, 2024, 10:00 Hrs [IST] Zenyaku Ko ...
Pharmabiz1d
Lipella Pharma completes dosing for first cohort in phase 2a trial of LP-310 for oral lichen planus
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, announced the completion of dosing for the first ...
Pharmabiz1d
Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer
Leads Biolabs receives US FDA orphan drug designation for anti-PD-L1/4-1BB bispecific antibody, LBL-024 for treatment of neuroendocrine cancer: Nanjing, China Saturday, November 2 ...
Pharmabiz1d
Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...
Pharmabiz1d
Philips introduces next-generation BlueSeal helium-free MRI system, integrated with AI-enabled Smart Reading
Philips introduces next-generation BlueSeal helium-free MRI system, integrated with AI-enabled Smart Reading: Amsterdam, the Netherlands Saturday, November 23, 2024, 13:00 Hrs [IS ...
Pharmabiz1d
CapeStart introduces MadeAi, a GenAI-enabled platform for life sciences that transforms literature review and other applications
CapeStart introduces MadeAi, a GenAI-enabled platform for life sciences that transforms literature review and other applications: Barcelona, Spain Saturday, November 23, 2024, 17: ...
Pharmabiz1d
China NMPA approves Merck’s Welireg to treat adult patients with certain types of von Hippel-Lindau disease-associated tumours
Merck, known as MSD outside of the United States and Canada, announced that the National Medical Products Administration (NMPA) in China has approved Welireg (belzutifan), for the treatment of adult ...
Pharmabiz2d
LAPIX Therapeutics announces positive results from phase 1 trial of LPX-TI641 for autoimmune diseases treatment
LAPIX Therapeutics announces positive results from phase 1 trial of LPX-TI641 for autoimmune diseases treatment: Boston Friday, November 22, 2024, 18:00 Hrs [IST] LAPIX Therapeuti ...
Pharmabiz2d
Anil Agarwal Foundation invests Rs. 437 crore to transform 1.73 crore lives across India in FY2023-24
Our Bureau, Mumbai Friday, November 22, 2024, 13:45 Hrs [IST] ...
Pharmabiz1d
SOPHiA GENETICS launches MSK-IMPACT powered with SOPHiA DDM at AMP 2024
SOPHiA GENETICS, a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT powered with SOPHiA DDM from the Association for Molecular Pathology ...
Pharmabiz2d
Kura Oncology & Kyowa Kirin ink global strategic collaboration to develop and commercialize ziftomenib in acute leukaemias
Kura Oncology & Kyowa Kirin ink global strategic collaboration to develop and commercialize ziftomenib in acute leukaemias: San Diego Friday, November 22, 2024, 14:00 Hrs [IST] Ku ...